Monthly
US$200
Billed every month
司美格鲁肽注射液
Companies, stages and changes, with each record available on this page.
Last 90 days: Accepted: 16 applicationsSupplement delivery: 10 applications
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Company names, approval identifiers and strengths are retained as recorded in the Chinese sources. Category labels include the original wording for verification.
Catalogue holders0View records ↓
Under-review filings92View records ↓
This year’s generic filers2View records ↓
NHSA approval numbers7View records ↓
API companies with A status0View records ↓
Chemical-drug catalogue
Loaded records: 0 holders; 0 in the quality-and-efficacy consistency-evaluation category, and 0 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| No matching records were found in the currently loaded source data; coverage dates are listed below. | ||||||
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 7 distinct approval numbers and 2 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| Novo Nordisk A/S | 国药准字SJ20240020 | 3.2mg/ml,3ml | Not stated by source | XA10BJS279B002010178997 | NHSA |
| Novo Nordisk Pharma AG | 国药准字SJ20210014 | 1.34mg/ml,1.5ml(预填充注射笔) | Category B (乙) | XA10BJS279B002010283568 | NHSA |
| Novo Nordisk A/S | 国药准字SJ20240021 | 2.27mg/ml,3ml | Not stated by source | XA10BJS279B002020178997 | NHSA |
| Novo Nordisk Pharma AG | 国药准字SJ20210015 | 1.34mg/ml,3ml(预填充注射笔) | Category B (乙) | XA10BJS279B002020283568 | NHSA |
| Novo Nordisk A/S | 国药准字SJ20240022 | 1.34mg/ml,3ml | Not stated by source | XA10BJS279B002030178997 | NHSA |
| Novo Nordisk A/S | 国药准字SJ20240023 | 1.34mg/ml,1.5ml | Not stated by source | XA10BJS279B002040178997 | NHSA |
| Novo Nordisk A/S | 国药准字SJ20240024 | 0.68mg/ml,1.5ml | Not stated by source | XA10BJS279B002050178997 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 92 filings and 17 distinct first applicants.
New drug 84 · Generic 8
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 江苏诺泰澳赛诺生物制药股份有限公司 | CXHS2600057 | New drug | 2026/04/22 | Not stated by source | CDE |
| 江苏诺泰澳赛诺生物制药股份有限公司 | CXHS2600056 | New drug | 2026/04/22 | Not stated by source | CDE |
| 江苏诺泰澳赛诺生物制药股份有限公司 | CXHS2600055 | New drug | 2026/04/22 | Not stated by source | CDE |
| 江苏诺泰澳赛诺生物制药股份有限公司 | CXHS2600054 | New drug | 2026/04/22 | Not stated by source | CDE |
| 江苏诺泰澳赛诺生物制药股份有限公司 | CXHS2600053 | New drug | 2026/04/09 | Not stated by source | CDE |
| 江苏诺泰澳赛诺生物制药股份有限公司 | CXHS2600052 | New drug | 2026/04/09 | Not stated by source | CDE |
| 江苏诺泰澳赛诺生物制药股份有限公司 | CXHS2600051 | New drug | 2026/04/09 | Not stated by source | CDE |
| 江苏诺泰澳赛诺生物制药股份有限公司 | CXHS2600050 | New drug | 2026/04/09 | Not stated by source | CDE |
| 复星万邦（江苏）医药集团有限公司 | CXSS2500122 | New drug | 2025/11/07 | Not stated by source | CDE |
| 复星万邦（江苏）医药集团有限公司 | CXSS2500121 | New drug | 2025/11/07 | Not stated by source | CDE |
| 复星万邦（江苏）医药集团有限公司 | CXSS2500120 | New drug | 2025/11/07 | Not stated by source | CDE |
| 复星万邦（江苏）医药集团有限公司 | CXSS2500119 | New drug | 2025/11/07 | Not stated by source | CDE |
| 连云港润众制药有限公司 | CXSS2600119 | New drug | 2026/08/04 | Not stated by source | CDE |
| 连云港润众制药有限公司 | CXSS2600118 | New drug | 2026/08/04 | Not stated by source | CDE |
| 连云港润众制药有限公司 | CXSS2600117 | New drug | 2026/08/04 | Not stated by source | CDE |
| 连云港润众制药有限公司 | CXSS2600116 | New drug | 2026/08/04 | Not stated by source | CDE |
| 连云港润众制药有限公司 | CXSS2600115 | New drug | 2026/08/04 | Not stated by source | CDE |
| 连云港润众制药有限公司 | CXSS2500140 | New drug | 2025/12/11 | Not stated by source | CDE |
| 连云港润众制药有限公司 | CXSS2500139 | New drug | 2025/12/11 | Not stated by source | CDE |
| 广州白云山拜迪生物医药有限公司;南京赛诺生物制药有限公司 | CXSL2601064 | New drug | 2026/09/24 | Not stated by source | CDE |
| 广州白云山拜迪生物医药有限公司;南京赛诺生物制药有限公司 | CXSL2601063 | New drug | 2026/09/24 | Not stated by source | CDE |
| 质肽药业（泰州）有限公司 | CXSS2600125 | New drug | 2026/08/17 | Not stated by source | CDE |
| 质肽药业（泰州）有限公司 | CXSS2600124 | New drug | 2026/08/17 | Not stated by source | CDE |
| 广州白云山拜迪生物医药有限公司 | CXSL2601141 | New drug | 2026/10/19 | Not stated by source | CDE |
| 广州白云山拜迪生物医药有限公司 | CXSL2601140 | New drug | 2026/10/19 | Not stated by source | CDE |
| 天津天士力之骄药业有限公司 | CYHL2600100 | Generic | 2026/09/16 | Not stated by source | CDE |
| 天津天士力之骄药业有限公司 | CYHL2600099 | Generic | 2026/09/16 | Not stated by source | CDE |
| 天津天士力之骄药业有限公司 | CYHL2600098 | Generic | 2026/09/16 | Not stated by source | CDE |
| 重庆宸安生物制药有限公司 | CXSS2600147 | New drug | 2026/09/07 | Not stated by source | CDE |
| 重庆宸安生物制药有限公司 | CXSS2600146 | New drug | 2026/09/07 | Not stated by source | CDE |
| 浙江三生蔓迪药业有限公司;深圳翰宇药业股份有限公司 | CYHS2601574 | Generic | 2026/07/02 | Not stated by source | CDE |
| 浙江三生蔓迪药业有限公司;深圳翰宇药业股份有限公司 | CYHS2601573 | Generic | 2026/07/02 | Not stated by source | CDE |
| 浙江三生蔓迪药业有限公司;深圳翰宇药业股份有限公司 | CYHS2601572 | Generic | 2026/07/02 | Not stated by source | CDE |
| 浙江三生蔓迪药业有限公司;深圳翰宇药业股份有限公司 | CYHS2601571 | Generic | 2026/07/02 | Not stated by source | CDE |
| 浙江三生蔓迪药业有限公司;深圳翰宇药业股份有限公司 | CYHS2601570 | Generic | 2026/07/02 | Not stated by source | CDE |
| 丽珠集团新北江制药股份有限公司 | CXSS2600085 | New drug | 2026/05/18 | Not stated by source | CDE |
| 丽珠集团新北江制药股份有限公司 | CXSS2600084 | New drug | 2026/05/18 | Not stated by source | CDE |
| 华润双鹤药业股份有限公司;深圳翰宇药业股份有限公司 | CXHS2600064 | New drug | 2026/05/08 | Not stated by source | CDE |
| 华润双鹤药业股份有限公司;深圳翰宇药业股份有限公司 | CXHS2600063 | New drug | 2026/05/08 | Not stated by source | CDE |
| 杭州中美华东制药江东有限公司 | CXSS2600070 | New drug | 2026/04/15 | Not stated by source | CDE |
| 杭州中美华东制药江东有限公司 | CXSS2600069 | New drug | 2026/04/15 | Not stated by source | CDE |
| 杭州中美华东制药江东有限公司 | CXSS2600068 | New drug | 2026/04/15 | Not stated by source | CDE |
| 杭州中美华东制药江东有限公司 | CXSS2600067 | New drug | 2026/04/15 | Not stated by source | CDE |
| 杭州中美华东制药江东有限公司 | CXSS2600066 | New drug | 2026/04/15 | Not stated by source | CDE |
| 成都倍特生物制药有限公司 | CXSS2600060 | New drug | 2026/04/01 | Not stated by source | CDE |
| 成都倍特生物制药有限公司 | CXSS2600059 | New drug | 2026/04/01 | Not stated by source | CDE |
| 成都倍特生物制药有限公司 | CXSS2600058 | New drug | 2026/04/01 | Not stated by source | CDE |
| 成都倍特生物制药有限公司 | CXSS2600057 | New drug | 2026/04/01 | Not stated by source | CDE |
| 成都倍特生物制药有限公司 | CXSS2600056 | New drug | 2026/04/01 | Not stated by source | CDE |
| 成都倍特生物制药有限公司 | CXSS2600055 | New drug | 2026/04/01 | Not stated by source | CDE |
| 成都倍特生物制药有限公司 | CXSS2600054 | New drug | 2026/04/01 | Not stated by source | CDE |
| 成都倍特生物制药有限公司 | CXSS2600053 | New drug | 2026/04/01 | Not stated by source | CDE |
| 成都倍特生物制药有限公司 | CXSS2600052 | New drug | 2026/04/01 | Not stated by source | CDE |
| 成都倍特生物制药有限公司 | CXSS2600051 | New drug | 2026/04/01 | Not stated by source | CDE |
| 杭州九源基因生物医药股份有限公司 | CXSS2600029 | New drug | 2026/02/25 | Not stated by source | CDE |
| 杭州九源基因生物医药股份有限公司 | CXSS2600028 | New drug | 2026/02/25 | Not stated by source | CDE |
| 杭州九源基因生物医药股份有限公司 | CXSS2600027 | New drug | 2026/02/25 | Not stated by source | CDE |
| 杭州九源基因生物医药股份有限公司 | CXSS2600026 | New drug | 2026/02/25 | Not stated by source | CDE |
| 杭州九源基因生物医药股份有限公司 | CXSS2600025 | New drug | 2026/02/25 | Not stated by source | CDE |
| 石药集团百克（山东）生物制药股份有限公司;石药集团欧意药业有限公司 | CXHS2500152 | New drug | 2025/12/06 | Not stated by source | CDE |
| 石药集团百克（山东）生物制药股份有限公司;石药集团欧意药业有限公司 | CXHS2500151 | New drug | 2025/12/06 | Not stated by source | CDE |
| 石药集团百克（山东）生物制药股份有限公司;石药集团欧意药业有限公司 | CXHS2500150 | New drug | 2025/12/06 | Not stated by source | CDE |
| 石药集团百克（山东）生物制药股份有限公司;石药集团欧意药业有限公司 | CXHS2500149 | New drug | 2025/12/06 | Not stated by source | CDE |
| 石药集团百克（山东）生物制药股份有限公司;石药集团欧意药业有限公司 | CXHS2500148 | New drug | 2025/12/06 | Not stated by source | CDE |
| 成都倍特生物制药有限公司 | CXSS2500089 | New drug | 2025/09/03 | Not stated by source | CDE |
| 成都倍特生物制药有限公司 | CXSS2500088 | New drug | 2025/09/03 | Not stated by source | CDE |
| 成都倍特生物制药有限公司 | CXSS2500087 | New drug | 2025/09/03 | Not stated by source | CDE |
| 成都倍特生物制药有限公司 | CXSS2500086 | New drug | 2025/09/03 | Not stated by source | CDE |
| 惠升生物制药股份有限公司 | CXSS2500084 | New drug | 2025/08/16 | Not stated by source | CDE |
| 惠升生物制药股份有限公司 | CXSS2500083 | New drug | 2025/08/16 | Not stated by source | CDE |
| 石药集团百克（山东）生物制药股份有限公司;石药集团欧意药业有限公司 | CXHS2500091 | New drug | 2025/08/05 | Not stated by source | CDE |
| 石药集团百克（山东）生物制药股份有限公司;石药集团欧意药业有限公司 | CXHS2500090 | New drug | 2025/08/05 | Not stated by source | CDE |
| 杭州中美华东制药江东有限公司 | CXSS2500043 | New drug | 2025/04/03 | Not stated by source | CDE |
| 杭州中美华东制药江东有限公司 | CXSS2500042 | New drug | 2025/04/03 | Not stated by source | CDE |
| 杭州中美华东制药江东有限公司 | CXSS2500041 | New drug | 2025/04/03 | Not stated by source | CDE |
| 杭州中美华东制药江东有限公司 | CXSS2500040 | New drug | 2025/04/03 | Not stated by source | CDE |
| 珠海联邦生物医药有限公司;珠海联邦制药股份有限公司中山分公司 | CXSS2500009 | New drug | 2025/01/24 | Not stated by source | CDE |
| 珠海联邦生物医药有限公司;珠海联邦制药股份有限公司中山分公司 | CXSS2500008 | New drug | 2025/01/24 | Not stated by source | CDE |
| 齐鲁制药有限公司 | CXHS2400095 | New drug | 2024/09/15 | Not stated by source | CDE |
| 齐鲁制药有限公司 | CXHS2400094 | New drug | 2024/09/15 | Not stated by source | CDE |
| 丽珠集团新北江制药股份有限公司 | CXSS2400059 | New drug | 2024/06/13 | Not stated by source | CDE |
| 丽珠集团新北江制药股份有限公司 | CXSS2400058 | New drug | 2024/06/13 | Not stated by source | CDE |
| 丽珠集团新北江制药股份有限公司 | CXSS2400057 | New drug | 2024/06/13 | Not stated by source | CDE |
| 杭州九源基因生物医药股份有限公司 | CXSS2400037 | New drug | 2024/04/03 | Not stated by source | CDE |
| 杭州九源基因生物医药股份有限公司 | CXSS2400036 | New drug | 2024/04/03 | Not stated by source | CDE |
| 杭州九源基因生物医药股份有限公司 | CXSS2400034 | New drug | 2024/04/03 | Not stated by source | CDE |
| 杭州九源基因生物医药股份有限公司 | CXSS2400032 | New drug | 2024/04/03 | Not stated by source | CDE |
| 珠海联邦生物医药有限公司;珠海联邦制药股份有限公司中山分公司 | CXSS2600183 | New drug | 2026/11/03 | Not stated by source | CDE |
| 珠海联邦生物医药有限公司;珠海联邦制药股份有限公司中山分公司 | CXSS2600182 | New drug | 2026/11/03 | Not stated by source | CDE |
| 珠海联邦生物医药有限公司;珠海联邦制药股份有限公司中山分公司 | CXSS2600181 | New drug | 2026/11/03 | Not stated by source | CDE |
| 珠海联邦生物医药有限公司;珠海联邦制药股份有限公司中山分公司 | CXSS2600180 | New drug | 2026/11/03 | Not stated by source | CDE |
| 珠海联邦生物医药有限公司;珠海联邦制药股份有限公司中山分公司 | CXSS2600179 | New drug | 2026/11/03 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 8 filings and 2 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 天津天士力之骄药业有限公司 | CYHL2600100 | Generic | 2026/09/16 | Not stated by source | CDE |
| 天津天士力之骄药业有限公司 | CYHL2600099 | Generic | 2026/09/16 | Not stated by source | CDE |
| 天津天士力之骄药业有限公司 | CYHL2600098 | Generic | 2026/09/16 | Not stated by source | CDE |
| 浙江三生蔓迪药业有限公司;深圳翰宇药业股份有限公司 | CYHS2601574 | Generic | 2026/07/02 | Not stated by source | CDE |
| 浙江三生蔓迪药业有限公司;深圳翰宇药业股份有限公司 | CYHS2601573 | Generic | 2026/07/02 | Not stated by source | CDE |
| 浙江三生蔓迪药业有限公司;深圳翰宇药业股份有限公司 | CYHS2601572 | Generic | 2026/07/02 | Not stated by source | CDE |
| 浙江三生蔓迪药业有限公司;深圳翰宇药业股份有限公司 | CYHS2601571 | Generic | 2026/07/02 | Not stated by source | CDE |
| 浙江三生蔓迪药业有限公司;深圳翰宇药业股份有限公司 | CYHS2601570 | Generic | 2026/07/02 | Not stated by source | CDE |
API registrations
Non-component matches: 0 companies with A status and 13 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 司美格鲁肽 | 浙江湃肽生物股份有限公司 | Y20260000317 | I | Exact ingredient | 2026/04/23 | CDE |
| 司美格鲁肽 | 江苏诺泰澳赛诺生物制药股份有限公司 | Y20250001233 | I | Exact ingredient | 2026/03/16 | CDE |
| 司美格鲁肽 | 翰宇药业（武汉）有限公司 | Y20250001408 | I | Exact ingredient | 2026/01/16 | CDE |
| 司美格鲁肽 | 福建基诺厚普生物科技有限公司 | Y20250001109 | I | Exact ingredient | 2025/11/06 | CDE |
| 司美格鲁肽 | 山西同达药业有限公司 | Y20250000541 | I | Exact ingredient | 2025/07/11 | CDE |
| 司美格鲁肽 | 湖北健翔生物制药有限公司 | Y20250000636 | I | Exact ingredient | 2025/07/08 | CDE |
| 司美格鲁肽 | 福建基诺厚普生物科技有限公司 | Y20250000482 | I | Exact ingredient | 2025/05/30 | CDE |
| 司美格鲁肽 | 齐鲁制药有限公司 | Y20240000820 | I | Exact ingredient | 2024/09/02 | CDE |
| 司美格鲁肽 | 海南中和药业股份有限公司 | Y20240000122 | I | Exact ingredient | 2024/02/22 | CDE |
| 司美格鲁肽 | 湖北健翔生物制药有限公司 | Y20230000037 | I | Exact ingredient | 2023/02/16 | CDE |
| 司美格鲁肽 | 江苏诺泰澳赛诺生物制药股份有限公司 | Y20220001086 | I | Exact ingredient | 2023/01/10 | CDE |
| 司美格鲁肽 | 苏州天马医药集团天吉生物制药有限公司 | Y20220001169 | I | Exact ingredient | 2023/01/09 | CDE |
| 司美格鲁肽 | 苏州立新制药有限公司 | Y20260000766 | I | Exact ingredient | 2026/10/30 | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/10 07:23. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
-
2026/11/03Accepted
珠海联邦生物医药有限公司;珠海联邦制药股份有限公司中山分公司
CXSS2600183
Fact date: 2026/11/03 · Site observation date: 2026/11/04
View source ↗ -
2026/11/03Accepted
珠海联邦生物医药有限公司;珠海联邦制药股份有限公司中山分公司
CXSS2600182
Fact date: 2026/11/03 · Site observation date: 2026/11/04
View source ↗ -
2026/11/03Accepted
珠海联邦生物医药有限公司;珠海联邦制药股份有限公司中山分公司
CXSS2600181
Fact date: 2026/11/03 · Site observation date: 2026/11/04
View source ↗ -
2026/11/03Accepted
珠海联邦生物医药有限公司;珠海联邦制药股份有限公司中山分公司
CXSS2600180
Fact date: 2026/11/03 · Site observation date: 2026/11/04
View source ↗ -
2026/11/03Accepted
珠海联邦生物医药有限公司;珠海联邦制药股份有限公司中山分公司
CXSS2600179
Fact date: 2026/11/03 · Site observation date: 2026/11/04
View source ↗ -
2026/10/20Supplement delivery
诺和诺德（中国）制药有限公司
JYSB2600022
Fact date: 2026/10/20 · Publication date: 2026/10/21 · Site observation date: 2026/11/03
Supplemental application; excluded from new marketing approvals.
View source · Table row 27 ↗ -
2026/10/20Supplement delivery
诺和诺德（中国）制药有限公司
JYSB2600021
Fact date: 2026/10/20 · Publication date: 2026/10/21 · Site observation date: 2026/11/03
Supplemental application; excluded from new marketing approvals.
View source · Table row 26 ↗ -
2026/10/20Supplement delivery
诺和诺德（中国）制药有限公司
JYSB2600020
Fact date: 2026/10/20 · Publication date: 2026/10/21 · Site observation date: 2026/11/03
Supplemental application; excluded from new marketing approvals.
View source · Table row 25 ↗ -
2026/10/20Supplement delivery
诺和诺德（中国）制药有限公司
JYSB2600019
Fact date: 2026/10/20 · Publication date: 2026/10/21 · Site observation date: 2026/11/03
Supplemental application; excluded from new marketing approvals.
View source · Table row 24 ↗ -
2026/10/20Supplement delivery
诺和诺德（中国）制药有限公司
JYSB2600018
Fact date: 2026/10/20 · Publication date: 2026/10/21 · Site observation date: 2026/11/03
Supplemental application; excluded from new marketing approvals.
View source · Table row 23 ↗ -
2026/10/19Accepted
-
2026/10/19Accepted
-
2026/10/16Supplement delivery
诺和诺德（中国）制药有限公司
JYSB2600197
Fact date: 2026/10/16 · Publication date: 2026/10/19 · Site observation date: 2026/11/03
Supplemental application; excluded from new marketing approvals.
View source · Table row 45 ↗ -
2026/10/16Supplement delivery
诺和诺德（中国）制药有限公司
JYSB2600196
Fact date: 2026/10/16 · Publication date: 2026/10/19 · Site observation date: 2026/11/03
Supplemental application; excluded from new marketing approvals.
View source · Table row 44 ↗ -
2026/10/16Supplement delivery
诺和诺德（中国）制药有限公司
JYSB2600195
Fact date: 2026/10/16 · Publication date: 2026/10/19 · Site observation date: 2026/11/03
Supplemental application; excluded from new marketing approvals.
View source · Table row 43 ↗ -
2026/10/16Supplement delivery
诺和诺德（中国）制药有限公司
JYSB2600194
Fact date: 2026/10/16 · Publication date: 2026/10/19 · Site observation date: 2026/11/03
Supplemental application; excluded from new marketing approvals.
View source · Table row 42 ↗ -
2026/10/16Supplement delivery
诺和诺德（中国）制药有限公司
JYSB2600193
Fact date: 2026/10/16 · Publication date: 2026/10/19 · Site observation date: 2026/11/03
Supplemental application; excluded from new marketing approvals.
View source · Table row 41 ↗ -
2026/09/24Accepted
广州白云山拜迪生物医药有限公司;南京赛诺生物制药有限公司
CXSL2601064
Fact date: 2026/09/24 · Site observation date: 2026/10/21
View source ↗ -
2026/09/24Accepted
广州白云山拜迪生物医药有限公司;南京赛诺生物制药有限公司
CXSL2601063
Fact date: 2026/09/24 · Site observation date: 2026/10/21
View source ↗ -
2026/09/16Accepted
-
2026/09/16Accepted
-
2026/09/16Accepted
-
2026/09/07Accepted
-
2026/09/07Accepted
-
2026/08/17Accepted
-
2026/08/17Accepted
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/10 07:27
- Chemical-drug catalogue
- Last successful update: 2026/11/10 07:23
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/10 07:25
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31
First index-page publication dates: 2026-10-26 to 2026-11-10; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/10 08:10 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 3/30; discovered pending details: 20. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to this drug
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Yearly
US$1,920
Billed every year
US$160 per month
Online subscriptions are not enabled. The form below registers interest; it does not charge or activate access.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
US$490
One payment · 12 months of access
Online comparison-table purchase is not enabled.
Billed by Creem, our merchant of record · Terms · Refund policy